Table 1. Open in new tab Baseline...

	Baseline Characteristics
Follow up, days^a	307 (95% CI: 298–317)	358 (95% CI: 321–394)	.010
Age, years^a	48.5 (95% CI: 47.9–49.0)	53.3 (95% CI: 51.6–55.0)	<.001
Sex, female	319 (21.4%)	42 (30.7%)	.017
BMI, kg/m^2,a	24.0 (95% CI: 23.6–24.3)	23.5 (95% CI: 22.7–24.2)	.230
Time since documented HIV infection, years^a	10.6 (95% CI: 10.2–10.9)	20.2 (95% CI: 19.2–21.3)	<.001
Time since ART initiation, years^a	8.5 (95% CI: 8.2–8.8)	17.3 (95% CI: 16.5–18.2)	<.001
Viral suppression before the switch to ABC/3TC/DTG, months^a	83.5 (95% CI: 82.5–88.1)	134.0 (95% CI: 126.5–141.5)	<.001
Patients with a previous documented VF	453 (30.4%)	127 (92.7%)	<.001
CD4 T-cell count nadir, mm^3,a	232 (95% CI: 224–241)	178 (95% CI: 155–201)	<.001
CD4 T-cell count at the time of the switch to ABC/3TC/DTG, mm^3,a	665 (95% CI: 649–680)	667 (95% CI: 612–722)	.929
Viral load before 1^st ART regimen, copies/ml, log10 transformed^a	4.84 (95% CI: 4.79–4.89)	4.77 (95% CI: 4.54–5.00)	.576
Prior AIDS diagnosis	277 (18.6%)	38 (27.7%)	.005
At least 2 TAMs	49 (3.3%)	58 (42.3%)	<.001
At least 3 TAMs	29 (1.9%)	41 (29.9%)	<.001
Distribution of M184V/I by cohort			<.001
Aquitaine	131 (8.8%)	37 (27.0%)
Antiviral Response Cohort Analysis (ARCA)	74 (5.0%)	14 (10.2%)
AIDS Therapy Evaluation in the Netherlands (ATHENA)	436 (29.3%)	24 (17.5%)
Italian Cohort of Antiretroviral-Naïve Patients (ICONA)	126 (8.5%)	6 (4.4%)
Swiss HIV Cohort Study (SHCS)	722 (48.5%)	56 (40.9%)
Treatment class before the switch to ABC/3TC/DTG (at any time)
NNRTI	897 (60.2%)	111 (81.0%)	<.001
INSTI	282 (18.9%)	25 (18.2%)	.933
PI	1082 (72.7%)	133 (97.1%)	<.001

Baseline Characteristics

Variables

Without M184V/I (N = 1489)

With M184V/I (N = 137)

P value

Follow up, days^a

307 (95% CI: 298–317)

358 (95% CI: 321–394)

.010

Age, years^a

48.5 (95% CI: 47.9–49.0)

53.3 (95% CI: 51.6–55.0)

<.001

Sex, female

319 (21.4%)

42 (30.7%)

.017

BMI, kg/m^2,a

24.0 (95% CI: 23.6–24.3)

23.5 (95% CI: 22.7–24.2)

.230

Time since documented HIV infection, years^a

10.6 (95% CI: 10.2–10.9)

20.2 (95% CI: 19.2–21.3)

<.001

Time since ART initiation, years^a

8.5 (95% CI: 8.2–8.8)

17.3 (95% CI: 16.5–18.2)

<.001

Viral suppression before the switch to ABC/3TC/DTG, months^a

83.5 (95% CI: 82.5–88.1)

134.0 (95% CI: 126.5–141.5)

<.001

Patients with a previous documented VF

453 (30.4%)

127 (92.7%)

<.001

CD4 T-cell count nadir, mm^3,a

232 (95% CI: 224–241)

178 (95% CI: 155–201)

<.001

CD4 T-cell count at the time of the switch to ABC/3TC/DTG, mm^3,a

665 (95% CI: 649–680)

667 (95% CI: 612–722)

.929

Viral load before 1^st ART regimen, copies/ml, log10 transformed^a

4.84 (95% CI: 4.79–4.89)

4.77 (95% CI: 4.54–5.00)

.576

Prior AIDS diagnosis

277 (18.6%)

38 (27.7%)

.005

At least 2 TAMs

49 (3.3%)

58 (42.3%)

<.001

At least 3 TAMs

29 (1.9%)

41 (29.9%)

<.001

Distribution of M184V/I by cohort

<.001

Aquitaine

131 (8.8%)

37 (27.0%)

Antiviral Response Cohort Analysis (ARCA)

74 (5.0%)

14 (10.2%)

AIDS Therapy Evaluation in the Netherlands (ATHENA)

436 (29.3%)

24 (17.5%)

Italian Cohort of Antiretroviral-Naïve Patients (ICONA)

126 (8.5%)

6 (4.4%)

Swiss HIV Cohort Study (SHCS)

722 (48.5%)

56 (40.9%)

Treatment class before the switch to ABC/3TC/DTG (at any time)

NNRTI

897 (60.2%)

111 (81.0%)

<.001

INSTI

282 (18.9%)

25 (18.2%)

.933

1082 (72.7%)

133 (97.1%)

<.001

	Baseline Characteristics
Follow up, days^a	307 (95% CI: 298–317)	358 (95% CI: 321–394)	.010
Age, years^a	48.5 (95% CI: 47.9–49.0)	53.3 (95% CI: 51.6–55.0)	<.001
Sex, female	319 (21.4%)	42 (30.7%)	.017
BMI, kg/m^2,a	24.0 (95% CI: 23.6–24.3)	23.5 (95% CI: 22.7–24.2)	.230
Time since documented HIV infection, years^a	10.6 (95% CI: 10.2–10.9)	20.2 (95% CI: 19.2–21.3)	<.001
Time since ART initiation, years^a	8.5 (95% CI: 8.2–8.8)	17.3 (95% CI: 16.5–18.2)	<.001
Viral suppression before the switch to ABC/3TC/DTG, months^a	83.5 (95% CI: 82.5–88.1)	134.0 (95% CI: 126.5–141.5)	<.001
Patients with a previous documented VF	453 (30.4%)	127 (92.7%)	<.001
CD4 T-cell count nadir, mm^3,a	232 (95% CI: 224–241)	178 (95% CI: 155–201)	<.001
CD4 T-cell count at the time of the switch to ABC/3TC/DTG, mm^3,a	665 (95% CI: 649–680)	667 (95% CI: 612–722)	.929
Viral load before 1^st ART regimen, copies/ml, log10 transformed^a	4.84 (95% CI: 4.79–4.89)	4.77 (95% CI: 4.54–5.00)	.576
Prior AIDS diagnosis	277 (18.6%)	38 (27.7%)	.005
At least 2 TAMs	49 (3.3%)	58 (42.3%)	<.001
At least 3 TAMs	29 (1.9%)	41 (29.9%)	<.001
Distribution of M184V/I by cohort			<.001
Aquitaine	131 (8.8%)	37 (27.0%)
Antiviral Response Cohort Analysis (ARCA)	74 (5.0%)	14 (10.2%)
AIDS Therapy Evaluation in the Netherlands (ATHENA)	436 (29.3%)	24 (17.5%)
Italian Cohort of Antiretroviral-Naïve Patients (ICONA)	126 (8.5%)	6 (4.4%)
Swiss HIV Cohort Study (SHCS)	722 (48.5%)	56 (40.9%)
Treatment class before the switch to ABC/3TC/DTG (at any time)
NNRTI	897 (60.2%)	111 (81.0%)	<.001
INSTI	282 (18.9%)	25 (18.2%)	.933
PI	1082 (72.7%)	133 (97.1%)	<.001

Table 1.

Open in new tab

Baseline Characteristics of Patients With or Without an Archived M184V/I Mutation

	Baseline Characteristics
Variables	Without M184V/I (N = 1489)	With M184V/I (N = 137)	P value
Follow up, days^a	307 (95% CI: 298–317)	358 (95% CI: 321–394)	.010
Age, years^a	48.5 (95% CI: 47.9–49.0)	53.3 (95% CI: 51.6–55.0)	<.001
Sex, female	319 (21.4%)	42 (30.7%)	.017
BMI, kg/m^2,a	24.0 (95% CI: 23.6–24.3)	23.5 (95% CI: 22.7–24.2)	.230
Time since documented HIV infection, years^a	10.6 (95% CI: 10.2–10.9)	20.2 (95% CI: 19.2–21.3)	<.001
Time since ART initiation, years^a	8.5 (95% CI: 8.2–8.8)	17.3 (95% CI: 16.5–18.2)	<.001
Viral suppression before the switch to ABC/3TC/DTG, months^a	83.5 (95% CI: 82.5–88.1)	134.0 (95% CI: 126.5–141.5)	<.001
Patients with a previous documented VF	453 (30.4%)	127 (92.7%)	<.001
CD4 T-cell count nadir, mm^3,a	232 (95% CI: 224–241)	178 (95% CI: 155–201)	<.001
CD4 T-cell count at the time of the switch to ABC/3TC/DTG, mm^3,a	665 (95% CI: 649–680)	667 (95% CI: 612–722)	.929
Viral load before 1^st ART regimen, copies/ml, log10 transformed^a	4.84 (95% CI: 4.79–4.89)	4.77 (95% CI: 4.54–5.00)	.576
Prior AIDS diagnosis	277 (18.6%)	38 (27.7%)	.005
At least 2 TAMs	49 (3.3%)	58 (42.3%)	<.001
At least 3 TAMs	29 (1.9%)	41 (29.9%)	<.001
Distribution of M184V/I by cohort			<.001
Aquitaine	131 (8.8%)	37 (27.0%)
Antiviral Response Cohort Analysis (ARCA)	74 (5.0%)	14 (10.2%)
AIDS Therapy Evaluation in the Netherlands (ATHENA)	436 (29.3%)	24 (17.5%)
Italian Cohort of Antiretroviral-Naïve Patients (ICONA)	126 (8.5%)	6 (4.4%)
Swiss HIV Cohort Study (SHCS)	722 (48.5%)	56 (40.9%)
Treatment class before the switch to ABC/3TC/DTG (at any time)
NNRTI	897 (60.2%)	111 (81.0%)	<.001
INSTI	282 (18.9%)	25 (18.2%)	.933
PI	1082 (72.7%)	133 (97.1%)	<.001

	Baseline Characteristics
Variables	Without M184V/I (N = 1489)	With M184V/I (N = 137)	P value
Follow up, days^a	307 (95% CI: 298–317)	358 (95% CI: 321–394)	.010
Age, years^a	48.5 (95% CI: 47.9–49.0)	53.3 (95% CI: 51.6–55.0)	<.001
Sex, female	319 (21.4%)	42 (30.7%)	.017
BMI, kg/m^2,a	24.0 (95% CI: 23.6–24.3)	23.5 (95% CI: 22.7–24.2)	.230
Time since documented HIV infection, years^a	10.6 (95% CI: 10.2–10.9)	20.2 (95% CI: 19.2–21.3)	<.001
Time since ART initiation, years^a	8.5 (95% CI: 8.2–8.8)	17.3 (95% CI: 16.5–18.2)	<.001
Viral suppression before the switch to ABC/3TC/DTG, months^a	83.5 (95% CI: 82.5–88.1)	134.0 (95% CI: 126.5–141.5)	<.001
Patients with a previous documented VF	453 (30.4%)	127 (92.7%)	<.001
CD4 T-cell count nadir, mm^3,a	232 (95% CI: 224–241)	178 (95% CI: 155–201)	<.001
CD4 T-cell count at the time of the switch to ABC/3TC/DTG, mm^3,a	665 (95% CI: 649–680)	667 (95% CI: 612–722)	.929
Viral load before 1^st ART regimen, copies/ml, log10 transformed^a	4.84 (95% CI: 4.79–4.89)	4.77 (95% CI: 4.54–5.00)	.576
Prior AIDS diagnosis	277 (18.6%)	38 (27.7%)	.005
At least 2 TAMs	49 (3.3%)	58 (42.3%)	<.001
At least 3 TAMs	29 (1.9%)	41 (29.9%)	<.001
Distribution of M184V/I by cohort			<.001
Aquitaine	131 (8.8%)	37 (27.0%)
Antiviral Response Cohort Analysis (ARCA)	74 (5.0%)	14 (10.2%)
AIDS Therapy Evaluation in the Netherlands (ATHENA)	436 (29.3%)	24 (17.5%)
Italian Cohort of Antiretroviral-Naïve Patients (ICONA)	126 (8.5%)	6 (4.4%)
Swiss HIV Cohort Study (SHCS)	722 (48.5%)	56 (40.9%)
Treatment class before the switch to ABC/3TC/DTG (at any time)
NNRTI	897 (60.2%)	111 (81.0%)	<.001
INSTI	282 (18.9%)	25 (18.2%)	.933
PI	1082 (72.7%)	133 (97.1%)	<.001

Abbreviations: ABC/3TC/DTG, abacavir/lamivudine/dolutegravir; ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; INSTI, integrase strand transfer inhibitors; IPW, inverse probability weighting analysis; NNRTI, nonnucleoside reverse transcriptase inhibitors; PI, protease inhibitor; TAM, thymidine analogue mutations.

^a Mean.

This Feature Is Available To Subscribers Only